BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cytokinetics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Cytokinetics's drugs run\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06736574-593@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Omecamtiv mecarbil: Phase 3 readout est. (NCT06736574)
DESCRIPTION:Omecamtiv mecarbil\, phase 3\, Heart Failure.\nStudy: Study Wit
 h Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Seve
 rely Reduced Ejection Fraction\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/omecamtiv-mecarbi
 l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 736574
URL:https://assetmemo.bio/drug/omecamtiv-mecarbil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848506-10786@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT04848506)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: Open-label Extension Study to Evaluate the Long-term Safety and To
 lerability of Aficamten in Adults With HCM\nEstimated primary completion: 
 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aficamten
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT048
 48506
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06412666-10786@assetmemo.bio
DTSTAMP:20261121T004054Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Myqorzo (Aficamten): Phase 2/3 readout est. (NCT06412666)
DESCRIPTION:Myqorzo (Aficamten)\, phase 2/3\, Hypertrophic Cardiomyopathy.\
 nStudy: A Study to Evaluate the Effect of Aficamten in Pediatric Patients 
 With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).\nEstimate
 d primary completion: January 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/aficamten#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06412666
URL:https://assetmemo.bio/drug/aficamten#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
